Earlier Investigations have Indicated a difference in the lipid profiles of drug-sensitive and drug-resistant tumor cells. This study was undertaken to evaluate the effect of alterations in the cellular lipid compositions by clofibrate (CPIB), an anti-hyperlipidemic agent, on mitoxantrone (Mtn) cytotoxicity in murine P388 leukemia cells sensitive (P388/S) and resistant (P388/Adr) to adriamycin and in human chronic myeloid leukemia (CML) cells. CPIB did not elicit any significant alterations in the lipid levels of P388/S cells, whereas in the P388/Adr cells it brought about a 14% and 49% decrease in the levels of cholesterol and triglyceride respectively. Inhibition of 3H-thymidine incorporation was utilized as a measure of cellular cytotoxicity. CPIB caused a dose dependent inhibition of DNA and RNA biosynthesis in P388/S, P388/Adr and CML cells. The combination of CPIB and Mtn induced a greater cytotoxicity in P388/Adr cells as compared to P388/S cells, as shown by enhanced inhibition of 3H-thymidine incorporation in P388/Adr cells. Similar results were observed when 3H-uridine was used as a measure of cellular cytotoxicity. These observations were further confirmed in fresh CML cell samples, in which the combination of CPIB with Mtn induced an irreversible and synergistic Inhibition of DNA biosynthesis. Results warrant extensive studies on CPIB as a clinical modulator to enhance the antiproliferative activity of Mtn.
Get full access to this article
View all access options for this article.
References
1.
AbellL.L., LevyB.B., BrodieB.B., KendallF.E.: A simplified method for the estimation of total cholesterol in serum and demonstration of its specificity.J. Biol. Chem., 195: 357–366, 1952.
2.
BaeyensJ.M.: Interactions between calcium channel blockers and non-cardiovascular drugs: Interactions with anticancer drugs.Pharmacology & Toxicology, 63: 1–7, 1988.
3.
BlighE.G., DyerW.J.: A rapid method of total lipid extraction and purification.Can. J. Biochem. Physiol., 37: 911–917, 1959.
ChitnisM.P., ParekhH.K., SatyamoorthyK.: Differential effect of clofibrate on adriamycin cytotoxicity in P388 murine leukemia sensitive and resistant to adriamycin.Tumori, 75: 100–104, 1989.
12.
DaltonW.S., GroganT.M., MeltzerP.S., SheperR.J., DureB.G., TaylorC.W., MillerT.P., SalmonS.E.: Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: Detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy.J. Clin. Oncol., 7: 415–424, 1989.
13.
DeucharsK.L., LingV.: P-glycoprotein and multidrug resistance in cancer chemotherapy.Semin. Oncol., 16: 156–165, 1988.
14.
FosterL.B., DunnR.T.: The ability of ceric ammonium sulfate in dilute sulfuric acid.Clin. Chem., 19: 338–340, 1973.
15.
FosterB.J., GrotzinngerK.R., McKoyW.M., RubinsteinL.V., HamiltonT.C.: Modulation of induced resistance to adriamycin in two human breast cancer cell lines with tamoxifen or perhexiline maleate.Cancer Chemother. Pharmacol., 22: 147–152, 1980.
16.
Gano-GauciD.F., RiordanJ.R.: Action of calcium antagonists on multidrug resistant cells: specific cytotoxicity independent of increased cancer drug accumulation.Biochem. Pharmacol., 36: 2115–2123, 1987.
17.
GottesmanM.M., PastanI.: Resistance to multiple chemotherapeutic agents in human cancer cells.TIPS, 9: 54–58, 1988.
18.
GottesmanM.M., PastanI.: The multidrug transporter: A double-edged sword.J. Biol. Chem., 263: 12163–12166, 1988.
19.
GuffyM.M., NorthJ.A., BurnsC.P.: Effect of cellular fatty acid alteration on adriamycin sensitivity in cultured L1210 murine leukemia cells.Cancer Res., 44: 1863–1866, 1984.
20.
HamadaH., HagiwaraK.I., NakajimaT., TsuruoT.: Phosphorylation of the 170,000 to 180,000 glycoprotein specific to multidrug resistant tumor cells: effects of verapamil, trifluoperazine and phorbol esters.Cancer Res., 47: 2860–2865, 1987.
21.
HillB.T., HoskingL.K., ShellardS.A., WhelanR.D.H.: Comparative effectiveness of mitoxantrone and doxorubicin in overcoming experimentally induced drug resistance in murine and human tumor cell line in vitro.Cancer Chemoter. Pharmacol., 23: 140–144, 1989.
22.
HolmesK.T., DyneE., WilliamP.G., MayG.L., TrippE., WrightL.C., MountfordC.E.: Vinblastine sensitivity of leukemic lymphoblasts modulated by serum lipids.FEBS Letts., 244: 103–107, 1989.
23.
HorioM., GottesmanM.M., PastanI.: ATP-dependent transport of vinblastine in vesicles from human multidrug resistant cells.Proc. Natl. Acad. Sci. USA, 85: 3580–3584, 1988.
24.
KeizerH.G., Van RijnJ., PinedoH.M., JoenjeH.: Effect of endogenous glutathione, superoxide dismutase, catalase and glutathione peroxidase on adriamycin tolerance of Chinese hamster ovary cells.Cancer Res., 48: 4493–4497, 1988.
25.
KlohsW.D., SteinK.R.W.: Possible link between the intrinsic drug resistance of colon tumors and a detoxification mechanism of intestinal cells.Cancer Res., 48: 3025–3030, 1988.
26.
KramerR.A., ZakherJ., KimG.: Role of glutathione redox cycle in acquired and de novo multidrug resistance.Science (Washington), 241: 694–696, 1988.
27.
LaiG.M., OzolsR.F., HamiltonT.C.: Role of glutathione on DNA repair in cisplatin resistant human ovarian cancer cell lines.J. Natl. Cancer Inst., 8: 535–539, 1989.
28.
MayG.L., WrightL.C., DyneM., MackinnonW.B., FoxR.M., MontfordC.E.: Plasma membrane lipid composition of vinblastine sensitive and resistant human leukemic lymphoblasts.Int. J. Cancer, 42: 728–733, 1988.
29.
MountfordC.E., WrightL.C.: Organisation of lipids in the plasma membranes of malignant and stimulated cells.A new model. Trends Biochem. Sci., 13: 172–177, 1988.
30.
ParekhH.K., SatyamoorthyK., AdvaniS.H., ChitnisM.P.: Sensitization of chronic myeloid leukemia cells to adriamycin cytotoxicity by clofibrate.Tumori, 76: 18–21, 1990.
31.
ParekhH.K., ChitnisM.P.: Evaluation of quinidiñe effect on the antitumor activity of adriamycin and mitoxantrone in adriamycin-sensitive and -resistant P388 leukemia cells.Selective Cancer Therapeutics, 6: 93–102, 1990.
32.
PommierY., KerriganD., SchwartzR.E.: Altered DNA topoisomerase II activity in Chinese hamster cells resistant to topoisomerase II inhibitors.Cancer Res., 46: 3075–3081, 1986.
33.
PradhanS.G., BasrurV.S., ChitnisM.P., AdvaniS.H.: In vitro enhancement of adriamycin cytotoxicity in human chronic myeloid leukemia cells exposed to verapamil.Oncology, 41: 406–408, 1984.
34.
RamuA., GlaubigerD., MagrathI.T., JoshiA.: Plasma membrane lipid structural order in doxorubicin sensitive and resistant P388 cells.Cancer Res., 43: 5533–5537, 1983.
35.
RamuA., GlaubigerD., WeintraubH.: Differences in lipid composition of doxorubicin-sensitive and -resistant P388 cells.Cancer Treat. Rep., 68: 637–641, 1984.
36.
RintoulD.A., CenterM.S.: Involvement of plasma membrane lipid structural order in adriamycin resistance in Chinese hamster lung cells.Cancer Res., 44: 4978–4982, 1984.
37.
SehestedM., SkovsgardT., van DeursB., Winther-NielsenH.: Increase in non-specific adsorptive endocytosis in anthracycline and vinca alkaloid resistant Ehrlich ascites tumor cell line.J. Natl. Cancer Inst., 78: 171–179, 1989.
38.
SondakV.K., KornE.L., KernD.H.: In vitro testing of chemotherapeutic combinations in a rapid thymidine incorporation assay.Int. J. Cell Cloning, 6: 378–391, 1988.
39.
TwentymanP.R.: Modification of cytotoxic drug resistance by non-immunosuppressive cyclosporins.Br. J. Cancer57: 254–258, 1988.
40.
ValerioteF., LinH.S.: Synergistic interactions of anticancer agents: A cellular perspective.Cancer Chemother. Rep59: 895–899, 1975.
41.
van der BleikA.M., BorstP.: Multidrug resistance.Adv. Cancer Res., 52: 165–203, 1989.
42.
ZijlistraE.G., de VriesE.G.F., MuskietF.A.J., MartiniI.A., Timmer-BosschaH., MulderN.H.: Influence of docasahexanoic acid in vitro on intracellular adriamycin concentration in lymphocytes and human adriamycin sensitive and resistant small cell lung cancer cell line, and on cytotoxicity in the tumor cell lines.Int. J. Cancer, 40: 850–856, 1987.
